The US Food and Drug Administration has given the green light to Cosette Pharmaceuticals to launch the first generic version of originator AbbVie’s Rectiv (nitroglycerin) ointment, 0.4%.
Cosette Launches First US Generic To AbbVie’s Rectiv
Commercial Shipments To Commence Imminently, With 180 Days Of CGT Exclusivity
Approval of Cosette’s first US generic to Rectiv came with a six-month exclusivity as the originator drug had “inadequate generic competition,” but the company has 75 days to enter the market.
More from Products
More from Generics Bulletin
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.